Leukemogenic risk of hydroxyurea therapy as a single agent in polycythemia vera and essential thrombocythemia: N- and K-ras mutations and microsatellite instability in chromosomes 5 and 7 in 69 patients

International Journal of Hematology

Volumn 75, Issue 4, 2002, Pages 394-400

  Mavrogianni, Despina ^a   Viniou, Nora ^a,b   Michali, Evi ^a   Terpos, Evangelos ^a   Meletis, John ^a   Vaiopoulos, George ^a   Madzourani, Marina ^a   Pangalis, Gerasimos ^a   Yataganas, Xenophon ^a   Loukopoulos, Dimitris ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b NONE   (Greece)

Author keywords

Microsatellite instability; Myeloproliferative disorders; Ras

Indexed keywords

HYDROXYUREA; MICROSATELLITE DNA;

ARTICLE; CHROMOSOME 5; CHROMOSOME 7; CODON; DISEASE COURSE; GENE MUTATION; HUMAN; INCIDENCE; LEUKEMIA; MAJOR CLINICAL STUDY; MICROSATELLITE INSTABILITY; MUTATIONAL ANALYSIS; ONCOGENE K RAS; ONCOGENE N RAS; PATHOGENESIS; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; RISK FACTOR; THROMBOTIC THROMBOCYTOPENIC PURPURA; ADOLESCENT; ADULT; AGED; CELL TRANSFORMATION; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; FEMALE; GENETICS; MALE; MIDDLE AGED; MUTATION; ONCOGENE RAS; PHYSIOLOGY; THROMBOCYTOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMES, HUMAN, PAIR 5; CHROMOSOMES, HUMAN, PAIR 7; FEMALE; GENES, RAS; HUMANS; HYDROXYUREA; INCIDENCE; LEUKEMIA; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; MUTATION; POLYCYTHEMIA VERA; THROMBOCYTOSIS;

EID: 0012844049     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02982131     Document Type: Article

References (31)

1. Vardiman JW. Chronic myelogenous leukemia and the myeloproliferative disorders. In: Knowles DM, ed. Neoplastic Hematopathology. Baltimore, Md: Williams and Wilkins; 1992:1405-1438.
2. Hoffman R, Silverstein MN, Hromas R. Primary thrombocythemia. In: Hoffman R, Benz EZ Jr, Shattil SJ, Furie B, Cohen HJ, Silbersten LE, eds. Hematology: Basic Principles and Practice. New York, NY: Churchill Livingstone; 1995:1174-1184.
3. Raskid WH, Jacobson R, Murphy S, Adamson JW, Fialkow PJ. Evidence for the involvement of B lymphoid cells in polycythemia vera and essential thrombocythemia. J Clin Invest. 1985;75:1388-1399.
4. Harrison CN, Gale RE, Machin SJ, Linch DC. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood. 1999;93:417-424.
5. El-Kasar N, Hetet G, Briere J, Grandchamp B. Clonality analysis of hematopoiesis in essential thrombocythemia: advantages of studying T lymphocytes and platelets. Blood. 1997;89:128-134.
6. Belucci S, Janvier M, Tobelen G, et al. Essential thrombocythemias: clinical evolutionary and biological data. Cancer. 1986;58:2440-2447.
7. Cervantens F, Tassies D, Salgado C, Rovira M, Pereira A, Rozman C. Acute transformation in nonleukemic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. Acta Hematol. 1991;85:124-127.
8. Landaw SA. Acute leukemia in polycythemia vera. Semin Hematol. 1986;23:156-165.
9. Najean Y, Deschamps A, Dresch C, Daniel MT, Rain JD, Arrago JP. Acute leukemia and myelodysplasia in polycythemia vera: a clinical study with long-term follow up. Cancer. 1988;61:89-95.
10. Sessarego M, Deferrari R, Dejana AM, et al. Cytogenetic analysis in essential thrombocythemia at diagnosis and at transformation: a 12-year study. Cancer Genet Cytogenet. 1989;43:57-65.
11. Gaidano G, Guerrasio A, Serra A, et al. Mutations in the p53 and Ras family genes are associated with tumor progression of bcr/abl negative chronic myeloproliferative disorders. Leukemia. 1993;7:946-953.
12. Gaidano G, Pastore C, Santini Y, et al. Genetic lesions associated with blastic transformation of polycythemia vera and essential thrombocythemia. Genes Chromosomes Cancer. 1997;19:250-255.
13. Miller SA, Dyhes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res. 1988;16:1215.
14. Jacobson D, Mills M. A highly sensitive assay for mutant ras genes and its application to the study of presentation and relapse genotypes in acute leukemia. Oncogene. 1994;9:553-563.
15. Collins S. The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression. Blood. 1987;70:1233-1244.
16. Fossum B, Olsen AC, Thorsby E, Gaudernack G. CD8+ cells from a patient with colon carcinoma, specific for a mutant p21-Ras-derived peptide (Gly13→Asp), are cytotoxic towards a carcinoma cell line harbouring the same mutation. Cancer Immunol Immunother. 1995;40:165-172.
17. Liang H, Fairman J, Claxton D, Nowell P, Green E, Nagarajan L. Molecular anatomy of chromosome 7q deletions in myeloid neoplasms: evidence for multiple critical loci. Proc Natl Acad Sci U S A. 1998;95:3781-3785.
18. Horrigan S, Westbrook C, Kim A, Banerjee M, Stock W, Larson R. Polymerase chain reaction-based diagnosis of del(5q) in acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval. Blood. 1996;88:2665-2670.
19. Neri A, Fracchiolla NS, Radaelli F, et al. p53 tumour suppressor gene and Ras oncogenes: molecular analysis in the chronic and leukaemic phases of essential thrombocythaemia. Br J Haematol. 1996;93:670-673.
20. Neuman W, Rubin C, Rachel R, et al. Chromosomal loss and deletion are the most common mechanisms for loss of heterozygosity from chromosomes 5 and 7 in malignant myeloid disorders. Blood. 1992;79:1501-1510.
21. LeBeau M, Espinosa R, Davis E, Eisenbart J, Larson R, Green E. Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid disorders. Blood. 1996;88:1930-1935.
22. Bilgrami S, Greenberg BR. Polycythemia rubra vera. Semin Oncol. 1995;22:307-326.
23. Weinfeld A, Swolin B, Westin J. Acute leukemia after hydroxyurea therapy in polycythemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications. Eur J Haematol. 1994;52:134-139.
24. Nand S, Messmore H, Fisher SG, Bird ML, Schultz W, Fisher RI. Leukemic transformation of PV: analysis of risk factors. Am J Hematol. 1990;34:32-36.
25. West WO. Hydroxyurea in the treatment of polycythemia vera: a prospective study of 100 patients over a 20 year period. South Med J. 1987; 80:323-327.
26. Sharon R. Treatment of polycythemia vera with hydroxyurea. Cancer. 1986;57:718-720.
27. Nand S, Stock W, Godwin J, Fisher S. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. Am J Hematol. 1996;52:42-46.
28. Furgerson JL, Vukelja SJ, Baker WS, O'Rourke TJ. Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea. Am J Hematol. 1996;51:137-140.
29. Pulik M, Lionnet F, Genet P, Petitdidier C, Jary L, Tuahri T. Acute myeloid leukemia evolving from polycythemia vera in a patient treated with hydroxyurea. Am J Hematol. 1996;53:207-208.
30. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with essential thrombocythaemia treated with busulfan and hydroxyurea: long-term follow-up in a randomized clinical trial. Br J Haematol. 2000;110:577-583.
31. Sterkers Y, Preudhomme C, Lai JL, et al. acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood. 1998;91:616-622.